biological DMARD

AB1319 RATES AND FACTORS ASSOCIATED WITH THERAPY DISCONTINUATION IN A MULTICENTER COHORT OF PATIENTS WITH GIANT CELL ARTERITIS FOLLOWED FOR 7 YEARS
M. Nitsa, C. Tsalapaki, A. Lazarini, E. Argyriou, V. Dania, K. Boki, G. Evangelatos, A. Iliopoulos, M. Pappa, P. P. Sfikakis, M. G. Tektonidou, A. Georgountzos, E. Kaltsonoudis, P. V. Voulgari, A. Drosos, E. Theotikos, C. Papagoras, T. Dimitroulas, A. Garyfallos, E. Kataxaki, G. Vosvotekas, D. Boumpas, E. Hadziyannis, D. Vassilopoulos

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 2008; DOI: 10.1136/annrheumdis-2024-eular.3583
AB1106 EFFICACY AND SAFETY OF BELIMUMAB IN SYSTEMIC LUPUS ERYTHEMATOSUS: MONOCENTRE STUDY
F. Riccio, M. Annunziata, M. Brancaccio, M. L. Marchesano, A. Milone, C. Parlati, M. Patrone, D. Mauro, S. Fasano, F. Ciccia, G. Cuomo

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 1882-1883; DOI: 10.1136/annrheumdis-2024-eular.6179
AB1125 REAL-WORLD SAFETY OF ANIFROLUMAB IN PATIENTS WITH SLE: A MULTI-NATIONAL PROGRAM OF SECONDARY DATABASE POST AUTHORIZATION SAFETY STUDIES
S. Correia, U. Katus, S. Huda, P. Kabadi, M. Arnaud, A. C. Santos, L. Nunez, J. Pietila, M. Lobier, J. Hedberg, S. Franzen, R. Corbe, D. Patel, E. Dareng

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 1894-1895; DOI: 10.1136/annrheumdis-2024-eular.1725
AB1139 ANALYSIS OF THE CLINICAL PROFILE OF A COHORT OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS NOT RESPONSIVE TO BELIMUMAB. SHORT-TERM EFFICACY OF ANIFROLUMAB
M. Camacho Halcón, D. Loaiza Cabello, A. Muñoz Jimenez, N. Garrido-Puñal, R. J. Gil Velez, S. García Morillo, F. J. García Hernández, R. Pertusa Mataix, M. Garrido Montes, E. Rubio Romero

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 1901-1902; DOI: 10.1136/annrheumdis-2024-eular.6168
AB0976 PLASMA PROTEIN INTER-ALPHA-TRYPSIN INHIBITOR HEAVY CHAIN 4 (ITIH4) LEVELS IN PATIENTS WITH axSpA AND RESPONSE TO TNF-INHIBITOR THERAPY
C. E. Mistegaard, A. Troldborg, A. G. Hansen, A. G. Jurik, R. M. Kiil, A. A. Christiansen, B. Schiøttz-Christensen, O. Hendricks, S. Juhl Pedersen, I. J. Sørensen, M. Østergaard, A. G. Loft, S. Thiel

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 1801-1802; DOI: 10.1136/annrheumdis-2024-eular.3810
AB0987 ANIFROLUMAB TREATMENT IMPROVES QUALITY OF LIFE AND DECREASES SYSTEMIC CORTICOSTEROID USE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
B. Deleuran, A. Troldborg, L. Remkus, D. Eek

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 1809-1810; DOI: 10.1136/annrheumdis-2024-eular.600
AB1000 ANIFROLUMAB IN SYSTEMIC LUPUS ERYTHEMATOSUS. SPANISH NATIONAL REGISTRY IN A REAL-WORLD SETTING
V. Calvo-Río, M. Retuerto-Guerrero, J. Font, I. Casafont-Solé, A. Mayo-Juanatey, J. J. Alegre Sancho, D. Freites, C. Hormigos, N. Garrido-Puñal, G. Gonzalez Arribas, J. R. Miguelez Sanchez, A. García-Valle, M. Ibañez, F. Lozano Morillo, Á. García Manzanares, S. Sandoval-Moreno, J. Cortés-Hernández, D. Palma Sanchez, L. Lojo, E. C. Cervantes Pérez, P. Collado, C. Arciniega Larios, L. Sala Icardo, E. Labrador-Sánchez, C. Peralta-Ginés, N. Plaza-Aulestia, M. Medina Malone, J. Rosas Gómez de Salazar, M. Corteguera, L. Cebrián-Méndez, F. A. Anton Pages, J. R. Lamúa Riazuelo, M. D. Fábregas Canales, M. J. Alados Hernández, M. Garijo Bufort, A. Pàmies, L. Sarabia De Ardanaz, R. Aguirre-del-Pino, J. A. Cabezas Lefler, A. Seijas-Lopez, M. D. C. Carrasco Cubero, A. Lopez-Ceron Cofiño, V. Ortiz-Santamaria, S. Castañeda, C. Bejerano, R. Blanco

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 1816-1817; DOI: 10.1136/annrheumdis-2024-eular.2481
AB1018 RILONACEPT USE IN LUPUS PERICARDITIS
A. Fava, M. Cammarata, L. Adamo

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 1827-1828; DOI: 10.1136/annrheumdis-2024-eular.5655
AB1024 EFFECT OF BELIMUMAB ON CLINICAL PROFILES IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) -ALTERATIONS OF IMMUNOLOGICAL ACTIVITY, DISEASE ACTIVITY AND DAILY LIVING SCORE (AS), AND ASSOCIATION BETWEEN IMPROVEMENT OF AS AND ABOVE FACTORS -
T. Ishizuka, K. Fujioka, H. Tani, M. Tangiku, A. Maeda, H. Oida, H. Okada, Y. Uno, I. Mori, M. Asano, H. Morita

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 1831; DOI: 10.1136/annrheumdis-2024-eular.621
AB1026 ANIFROLUMAB FOR PATIENTS WITH MODERATE TO SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS: INTERIM ANALYSIS OF A RETROSPECTIVE COHORT STUDY
E. M. Vital, F. Chasset, R. Faria, L. M. Carter, D. Kielar, S. Y. Chen, L. Carty, J. Natman, M. Waratani

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 1832; DOI: 10.1136/annrheumdis-2024-eular.747

Log in using your username and password

Main menu

Log in using your username and password

You are here

biological DMARD

Pages